Shoreline Biosciences vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
iPSC-derived allogeneic NK cell and macrophage immunotherapy platform. $183M raised; $300M+ total with partnerships; SMART manufacturing for off-the-shelf cancer cell therapy.
About
Shoreline Biosciences is a clinical-stage biotechnology company harnessing induced pluripotent stem cells (iPSCs) to develop allogeneic, off-the-shelf cellular immunotherapies. The company differentiates iPSCs into natural killer (iNK) cells and macrophages (iMACs) engineered to attack cancer and autoimmune targets. Its proprietary SLEEK knock-in gene-editing technology and industry-leading SMART manufacturing platform are designed to produce scalable, affordable cell therapies without donor matching constraints. Shoreline has raised $183M in equity across two rounds from 18 investors and has secured corporate partnerships valued at over $300M in aggregate support. The pipeline spans both solid tumors and hematologic malignancies, with autoimmune disorder programs announced in late 2024.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.